CY1108799T1 - Αντισωμα αντι- ccr5 - Google Patents

Αντισωμα αντι- ccr5

Info

Publication number
CY1108799T1
CY1108799T1 CY20091100160T CY091100160T CY1108799T1 CY 1108799 T1 CY1108799 T1 CY 1108799T1 CY 20091100160 T CY20091100160 T CY 20091100160T CY 091100160 T CY091100160 T CY 091100160T CY 1108799 T1 CY1108799 T1 CY 1108799T1
Authority
CY
Cyprus
Prior art keywords
ccr5
atcc deposit
deposit designation
plasmid designated
designation pta
Prior art date
Application number
CY20091100160T
Other languages
English (en)
Inventor
William C Olson
Paul J Maddon
Maximiliano Vasquez
Paul R Hinton
Naoya Tsurushita
Original Assignee
Progenics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals, Inc. filed Critical Progenics Pharmaceuticals, Inc.
Publication of CY1108799T1 publication Critical patent/CY1108799T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση κατευθύνεται προς ένα αντίσωμα anti-CCR5 που περιλαμβάνει (i) δύο ελαφρές αλυσίδες, όπου κάθε ελαφρή αλυσίδα περιλαμβάνει το προϊόν έκφρασης ενός πλασμιδίου που συμβολίζεται με pVK: HuPRO140-VK, Αριθμός Κατάθεσης ATCC No. ΡΤΑ-4097, και (ii) δύο βαριές αλυσίδες, όπου κάθε βαριά αλυσίδα περιλαμβάνει είτε το προϊόν έκφρασης ενός πλασμιδίου που συμβολίζεται με pVgl: HuPRO140 HG2-VH, Αριθμός Κατάθεσης ATCC No. ΡΤΑ-4098 ή ενός πλασμιδίου που συμβολίζεται με pVgl: HuPRO140 (mut B+D+I)-VH Αριθμός Κατάθεσης ATCC No. PTA-4099, ή ένα κλάσμα αυτού, που συνδέεται με το CCR5 στην επιφάνεια ενός ανθρώπινου κυττάρου.
CY20091100160T 2002-02-22 2009-02-12 Αντισωμα αντι- ccr5 CY1108799T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8112802A 2002-02-22 2002-02-22
EP03713632A EP1478738B1 (en) 2002-02-22 2003-02-21 Anti-ccr5 antibody

Publications (1)

Publication Number Publication Date
CY1108799T1 true CY1108799T1 (el) 2014-04-09

Family

ID=27765254

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100160T CY1108799T1 (el) 2002-02-22 2009-02-12 Αντισωμα αντι- ccr5

Country Status (20)

Country Link
EP (2) EP2058006A1 (el)
JP (1) JP2006508631A (el)
KR (1) KR20050004784A (el)
CN (1) CN1780907B (el)
AT (1) ATE414142T1 (el)
AU (1) AU2003217674C1 (el)
CA (1) CA2476901C (el)
CY (1) CY1108799T1 (el)
DE (1) DE60324664D1 (el)
DK (1) DK1478738T3 (el)
ES (1) ES2316740T3 (el)
HK (1) HK1072272A1 (el)
IL (1) IL163655A0 (el)
MX (1) MXPA04008153A (el)
NO (1) NO20043971L (el)
NZ (2) NZ561465A (el)
PT (1) PT1478738E (el)
RU (1) RU2322454C2 (el)
WO (1) WO2003072766A1 (el)
ZA (1) ZA200406765B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200720289A (en) * 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US20070026441A1 (en) * 2005-07-22 2007-02-01 Olson William C Methods for reducing viral load in HIV-1-infected patients
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009001204A (es) 2006-08-17 2009-02-11 Hoffmann La Roche Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico.
WO2008037419A1 (en) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Antibodies against ccr5 and uses thereof
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
CA2736029A1 (en) * 2008-09-05 2010-03-11 Duke University Anti-lipid antibodies
JP5937523B2 (ja) * 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN107847514A (zh) 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
WO2017087547A1 (en) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
WO2021146323A1 (en) * 2020-01-13 2021-07-22 Cytodyn Inc. Ccr5 binding agent for treatment of ccr5 positive metastatic breast cancer
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
EP2088158A3 (en) * 1998-12-16 2010-01-20 Progenics Pharmaceuticals, Inc. Monoclonal antibody against the CCR5 chemokine receptor
JP3459386B2 (ja) 1999-10-15 2003-10-20 Ｓｍｃ株式会社 可逆式取付機構を有する流体圧機器

Also Published As

Publication number Publication date
ATE414142T1 (de) 2008-11-15
EP1478738A1 (en) 2004-11-24
ES2316740T3 (es) 2009-04-16
NZ534947A (en) 2008-03-28
IL163655A0 (en) 2005-12-18
WO2003072766A1 (en) 2003-09-04
HK1072272A1 (en) 2005-08-19
CA2476901A1 (en) 2003-09-04
AU2003217674C1 (en) 2009-03-26
PT1478738E (pt) 2009-02-16
CN1780907A (zh) 2006-05-31
EP1478738A4 (en) 2006-05-31
CN1780907B (zh) 2011-06-15
EP1478738B1 (en) 2008-11-12
EP2058006A1 (en) 2009-05-13
JP2006508631A (ja) 2006-03-16
ZA200406765B (en) 2006-06-28
NO20043971L (no) 2004-11-16
CA2476901C (en) 2012-10-09
DE60324664D1 (de) 2008-12-24
MXPA04008153A (es) 2005-07-05
NZ561465A (en) 2009-04-30
KR20050004784A (ko) 2005-01-12
RU2322454C2 (ru) 2008-04-20
AU2003217674A1 (en) 2003-09-09
AU2003217674B2 (en) 2008-10-30
RU2004128252A (ru) 2005-04-10
DK1478738T3 (da) 2009-03-09

Similar Documents

Publication Publication Date Title
CY1108799T1 (el) Αντισωμα αντι- ccr5
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
CY1115730T1 (el) Θεραπευτικοι επιτοποι και χρησεις αυτων
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
DK3572508T1 (da) Hybrid-antistoffer indeholdende tunge kæder med humane VDJ områder og tungkæde konstante områder fra mus og lette kæder med humane VJ områder og letkæde konstante områder fra mus.
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
ATE187494T1 (de) Multivalente einkettige antikörper
RS54450B1 (en) ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
WO2005003171A3 (en) Modified antibody fragments
DE69533675D1 (de) Monoklonaler antikörper gegen rhesus d (d7c2)
WO2003055527A3 (en) Immunoconjugates useful for treatment of tumours
IN2009KN02655A (el)
EP2267034A3 (en) Gold-binding protein and use thereof
FI960567A (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
DE69409225T2 (de) Verbindungen für zielrichtung
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
FR2841905B1 (fr) Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
WO2004050849A8 (en) Recombinant immunotoxin and use in treating tumors
WO2004029214A3 (en) Lfa-1 alpha subunit antibodies and methods of use
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους